Close Menu

NEW YORK – Elevation Oncology on Wednesday announced that it had raised $65 million in a Series B financing round, led by new investors VenBio Partners and Cormorant Asset Management.

Boxer Capital of Tavistock Group, Janus Henderson, Samsara Biocapital, Vivo Capital, and existing investors also participated in the latest round, the funds from which Elevation will put toward completing enrollment in the Phase II CRESTONE trial and other corporate development activities.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.

Dec
02
Sponsored by
Qiagen

The Phosphoinositide 3-Kinase (PI3K) pathway is one of the most frequently altered pathways in human cancer and plays a significant role in disease progression and resistance to endocrine therapy.